Australia's PainChek drops most in nearly 8 years on FDA approval delay
View all comments(0)
PainChek PCK.AX plunges as much as ~31% to A$0.038; marks biggest intraday pct drop since June 18, 2017
Stock hits lowest since May 7
Medical devices maker flags potential delay in U.S. FDA clearance for its pain assessment app
Expects clearance by mid-to-late September instead of the first half of 2025 anticipated earlier
About 14.3 mln shares traded in stock's busiest day since February 18, 2021
PCK last up 21.8%, taking YTD gains to 48.3%
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.